Pharmacological modulation of the endocannabinoid signalling alters binge‐type eating behaviour in female rats
- 27 May 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 169 (4) , 820-833
Abstract
Background and Purpose: Binge eating disorder (BED) is characterized by excessive food intake during short periods of time. Recent evidence suggests that alterations in the endocannabinoid signalling could be involved in the pathophysiology of BED. In this study, we investigated whether pharmacological manipulation of endocannabinoid transmission may be effective in modulating the aberrant eating behaviour present in a validated rat model of BED.Experimental Approach: Binge‐type eating was induced in female rats by providing limited access to an optional source of dietary fat (margarine). Rats were divided into three groups, all with ad libitum access to chow and water: control (C), with no access to margarine; low restriction (LR), with 2 h margarine access 7 days a week; high restriction (HR), with 2 h margarine access 3 days a week.Key Results: Compared with the LR group, the HR group consumed more margarine and this was accompanied by an increase in body weight. The cannabinoid CB1/CB2 receptor agonist Δ9‐tetrahydrocannabinol significantly increased margarine intake selectively in LR rats, while the fatty acid amide hydrolase inhibitor URB597 showed no effect. The CB1 receptor inverse agonist/antagonist rimonabant dose‐dependently reduced margarine intake in HR rats. Notably, in HR rats, chronic treatment with a low dose of rimonabant induced a selective long‐lasting reduction in margarine intake that did not develop tolerance, and a significant and persistent reduction in body weight.Conclusions and Implications: Chronic pharmacological blockade of CB1 receptors reduces binge eating behaviour in female rats and may prove effective in treating BED, with an associated significant reduction in body weight.Linked Articles: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue‐4 & http://dx.doi.org/10.1111/bph.2012.167.issue‐8Keywords
This publication has 94 references indexed in Scilit:
- Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding densityPhysiology & Behavior, 2012
- Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviorsPharmacology & Therapeutics, 2011
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- DSM‐IV psychiatric disorder comorbidity and its correlates in binge eating disorderInternational Journal of Eating Disorders, 2008
- The endocannabinoid system in brain reward processesBritish Journal of Pharmacology, 2008
- The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibitionNeuropharmacology, 2008
- Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptorsBritish Journal of Pharmacology, 2007
- Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c‐Fos expression in the hypothalamusBritish Journal of Pharmacology, 2007
- Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primatesPharmacology Biochemistry and Behavior, 2007
- The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey ReplicationBiological Psychiatry, 2007